Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Oncogene ; 32(33): 3809-18, 2013 Aug 15.
Article in English | MEDLINE | ID: mdl-22964631

ABSTRACT

Malignant cell transformation commonly results in the deregulation of thousands of cellular genes, an observation that suggests a complex biological process and an inherently challenging scenario for the development of effective cancer interventions. To better define the genes/pathways essential to regulating the malignant phenotype, we recently described a novel strategy based on the cooperative nature of carcinogenesis that focuses on genes synergistically deregulated in response to cooperating oncogenic mutations. These so-called 'cooperation response genes' (CRGs) are highly enriched for genes critical for the cancer phenotype, thereby suggesting their causal role in the malignant state. Here, we show that CRGs have an essential role in drug-mediated anticancer activity and that anticancer agents can be identified through their ability to antagonize the CRG expression profile. These findings provide proof-of-concept for the use of the CRG signature as a novel means of drug discovery with relevance to underlying anticancer drug mechanisms.


Subject(s)
Antineoplastic Agents/pharmacology , Drug Discovery/methods , Neoplasms, Experimental/drug therapy , Neoplasms, Experimental/genetics , Transcriptome/drug effects , Transcriptome/genetics , Animals , Blotting, Western , Chromatin Immunoprecipitation , Mice , Mice, Nude , Phenotype , Real-Time Polymerase Chain Reaction
2.
J Biol Regul Homeost Agents ; 15(2): 123-9, 2001.
Article in English | MEDLINE | ID: mdl-11501969

ABSTRACT

The androgen receptor (AR) is a member of the nuclear receptor (NR) superfamily that mediates the effects of androgens on target tissues. Over the last decade, it has become apparent that NRs require accessory factors for optimal activation of target gene expression. Numerous NR coregulators have been identified, with diverse structures and potential mechanisms of coregulation, creating an increasingly complicated picture of NR action. Due to the expanding complexity of the coregulator field, this review will focus on the AR ligand-binding domain (LBD) and N-terminal interacting proteins identified by our lab. The LBD-interacting proteins ARA70, ARA55 and ARA54 were first characterized and ARA70 was found to have a relatively higher specificity for the AR in human prostate cancer DU145 cells. Characterization of the functional relationship between the AR and these coregulators indicated that ARA70 and ARA55 could enhance the androgenic effects of 17beta-estradiol (E2) and hydroxyflutamide (HF), an antiandrogen commonly used in the treatment of prostate cancer. ARA160, an AR N-terminal interacting protein also known as TATA element modulatory factor (TMF), was subsequently shown to cooperate with ARA70 in enhancing AR activity. Another AR N-terminal interacting protein, ARA24, interacted with the poly-Q tract, a region within the N-terminus of the AR linked to Kennedy's disease (X-linked spinal and bulbar muscular atrophy). More recently, our lab has identified ARA267, a SET domain containing protein, and supervillin, an F-actin binding protein, as AR coregulators. Collectively, the data from these studies indicate that these coregulators are necessary for optimal AR transactivation. Interruption of the interaction between AR and these proteins may serve as a new therapeutic target in the treatment of prostate cancer.


Subject(s)
Intracellular Signaling Peptides and Proteins , Neoplasms, Hormone-Dependent/metabolism , Nuclear Proteins , Oncogene Proteins , Prostatic Neoplasms/metabolism , Receptors, Androgen/metabolism , Saccharomyces cerevisiae Proteins , Acetyltransferases/metabolism , Binding Sites , Carrier Proteins/metabolism , DNA-Binding Proteins/metabolism , Histone Acetyltransferases , Histone Methyltransferases , Histone-Lysine N-Methyltransferase , Humans , LIM Domain Proteins , Ligands , Male , Membrane Proteins/metabolism , Microfilament Proteins/metabolism , Neoplasms, Hormone-Dependent/genetics , Nuclear Receptor Coactivators , Prostatic Neoplasms/genetics , Receptor, ErbB-2/metabolism , Receptors, Androgen/genetics , Trans-Activators/metabolism , Transcription Factors/metabolism , Transcriptional Activation , Tumor Cells, Cultured , ran GTP-Binding Protein/metabolism
3.
Brain Res Mol Brain Res ; 80(1): 99-108, 2000 Aug 14.
Article in English | MEDLINE | ID: mdl-11039733

ABSTRACT

Recently, a new family of potassium channels with two pore domains in tandem and four transmembrane segments has been identified. Seven functional mammalian channels have been reported at this time. These channels give rise to baseline potassium currents because they are not gated by voltage and exhibit spontaneous activity at all membrane potentials. Although the physiological role of these ion channels has yet to be determined, three mammalian members of this family (TREK-1, TASK-1, TASK-2) are activated by volatile anesthetics and may therefore contribute to the central nervous system (CNS) depression produced by volatile anesthetics. In this study we used northern blot analysis and immunohistochemical localization to determine the expression of TASK-1 subunits in the CNS. TASK-1 immunoreactivity was prominently found in astrocytes of the hippocampus, in the median eminence, in the choroid plexus, and the granular layer, Purkinje cell layer, and molecular layer of the cerebellum. In the spinal cord, strong TASK-I immunoreactivity was seen in ependymal cells lining the central canal and in white matter. These findings suggest a role for the TASK-1 channel in the production of cerebrospinal fluid and function of hypothalamic neurosecretory cells.


Subject(s)
Central Nervous System/chemistry , Nerve Tissue Proteins/analysis , Potassium Channels, Tandem Pore Domain , Potassium Channels/analysis , Amino Acid Sequence , Animals , Electrophoresis, Polyacrylamide Gel , Immunohistochemistry , Male , Mice , Microscopy, Fluorescence , Molecular Sequence Data , Rats , Rats, Sprague-Dawley
4.
J Formos Med Assoc ; 99(12): 885-94, 2000 Dec.
Article in English | MEDLINE | ID: mdl-11155740

ABSTRACT

Several new androgen receptor (AR) coregulators, including ARA70, ARA55, ARA54, ARA160 and ARA24, associated with the N-terminal or the ligand-binding domain (LBD) of AR, have been identified by our group. We first identified the AR-LBD coregulators ARA70, ARA55, and ARA54. Our previous reports suggest that ARA70 can enhance the androgenic activity of 17 beta-estradiol (E2) and antiandrogens toward AR. It is of interest to compare and determine if the specificity of sex hormones and antiandrogens can be modulated by different coregulators. Our results indicate that, ARA70 is the best coregulator for increasing the androgenic activity of E2. Only ARA70 and ARA55 were able to significantly increase the androgenic activity of hydroxyflutamide, the active metabolite of a widely-used antiandrogen for the treatment of prostate cancer. Furthermore, our results suggest that among the LBD coregulators, ARA70 has a relatively high specificity for AR in the human prostate cancer cell line DU145. Together, our data suggest that the androgenic activity of some sex hormones and antiandrogens can be modulated by selective AR coactivators. In addition to the AR-LBD associated proteins, ARA24 and ARA160 have been identified as AR coregulators, interacting with the AR N-terminal instead of the LBD. Functional analysis revealed that the AR N-terminal coregulator ARA160 could cooperate with the AR LBD-associated coregulator ARA70. Our data indicate that ARA24 could also interact with AR, and that this binding is decreased by an expanding poly-glutamine (Q) length within AR. The length of the poly-Q stretch in the AR N-terminal domain is inversely correlated with the transcriptional activity of AR. Our data suggest that optimal AR transactivation may require interaction of AR with AR coregulators. The identification of factors or peptides that can interrupt androgen-mediated AR-ARA interactions may be useful in the development of better antiandrogens for treating androgen-related diseases, such as prostate cancer.


Subject(s)
Prostatic Neoplasms/metabolism , Receptors, Androgen/metabolism , Trans-Activators/physiology , Androgen Antagonists/pharmacology , Animals , Binding Sites , Humans , Male , Prostatic Neoplasms/genetics , Receptors, Androgen/genetics , Transcriptional Activation , Tumor Cells, Cultured
SELECTION OF CITATIONS
SEARCH DETAIL
...